DE69030545D1 - Aufspüren und Behandeln von Infektionen durch Verwendung von Immunokonjukaten - Google Patents

Aufspüren und Behandeln von Infektionen durch Verwendung von Immunokonjukaten

Info

Publication number
DE69030545D1
DE69030545D1 DE69030545T DE69030545T DE69030545D1 DE 69030545 D1 DE69030545 D1 DE 69030545D1 DE 69030545 T DE69030545 T DE 69030545T DE 69030545 T DE69030545 T DE 69030545T DE 69030545 D1 DE69030545 D1 DE 69030545D1
Authority
DE
Germany
Prior art keywords
antibody
pathogen
diagnostic
focus
composite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69030545T
Other languages
English (en)
Other versions
DE69030545T2 (de
Inventor
Milton David Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of DE69030545D1 publication Critical patent/DE69030545D1/de
Publication of DE69030545T2 publication Critical patent/DE69030545T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE69030545T 1989-08-24 1990-08-24 Aufspüren und Behandeln von Infektionen durch Verwendung von Immunokonjukaten Expired - Fee Related DE69030545T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39956689A 1989-08-24 1989-08-24

Publications (2)

Publication Number Publication Date
DE69030545D1 true DE69030545D1 (de) 1997-05-28
DE69030545T2 DE69030545T2 (de) 1997-08-07

Family

ID=23580041

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69030545T Expired - Fee Related DE69030545T2 (de) 1989-08-24 1990-08-24 Aufspüren und Behandeln von Infektionen durch Verwendung von Immunokonjukaten

Country Status (13)

Country Link
EP (1) EP0417927B1 (de)
JP (1) JPH07121880B2 (de)
KR (1) KR0179953B1 (de)
AT (1) ATE151994T1 (de)
AU (1) AU636172B2 (de)
CA (1) CA1339415C (de)
DE (1) DE69030545T2 (de)
ES (1) ES2100164T3 (de)
IE (1) IE903071A1 (de)
IL (1) IL95457A (de)
SG (1) SG46451A1 (de)
WO (1) WO1991002541A1 (de)
ZA (1) ZA906703B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
GB9517758D0 (en) * 1995-08-31 1995-11-01 Imutran Ltd Compositions and their uses
ITRM960808A1 (it) * 1996-11-26 1998-05-26 Rossolini Gianmaria Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia
DE19809785C2 (de) * 1998-03-08 2000-02-10 Wolfgang Bergter Radioimmunpharmakon zur Behandlung der HIV-1-Infektion
JP2002519334A (ja) * 1998-06-29 2002-07-02 ベルクター，ヴォルフガンク αエミッタとβエミッタとを主成分とする抗ウイルスおよび抗レトロウイルス放射免疫薬剤
CA2475247C (en) * 2002-02-07 2015-08-04 Massachusetts Institute Of Technology Anti-pathogen treatments
EP1419786A1 (de) 2002-11-13 2004-05-19 Bracco Imaging S.p.A. Verfahren zur quantitativen und selektiven Funktionalisierung von Immunoglobulin-Fab-Fragmenten, deren Konjugate und deren Zusammensetzungen
JP4928964B2 (ja) 2007-01-30 2012-05-09 本田技研工業株式会社 車両のスイングアーム式懸架装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3173342D1 (en) * 1980-03-03 1986-02-13 Milton David Goldenberg Agent for tumor localization and therapy with labeled antibodies and antibody fragments
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
EP0149709B2 (de) * 1983-07-29 1995-11-29 Milton David Goldenberg Verfahren zur Erhöhung der Zielspezifizität in Antikörperbestimmungen und zur Räumung von nichtzielspezifischen diagnostischen und therapeutischen Faktoren
US4855227A (en) * 1985-06-07 1989-08-08 Institute For Medical Research Rapid detection of mycoplasmas
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
ATE122237T1 (de) * 1987-05-29 1995-05-15 Tanox Biosystems Inc Hiv-1 neutralisierende monoklonale antikörper.
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions

Also Published As

Publication number Publication date
EP0417927A1 (de) 1991-03-20
DE69030545T2 (de) 1997-08-07
AU636172B2 (en) 1993-04-22
ZA906703B (en) 1991-06-26
EP0417927B1 (de) 1997-04-23
JPH04506217A (ja) 1992-10-29
ES2100164T3 (es) 1997-06-16
KR0179953B1 (ko) 1999-03-20
IE903071A1 (en) 1991-02-27
SG46451A1 (en) 1998-02-20
AU6408290A (en) 1991-04-03
ATE151994T1 (de) 1997-05-15
IL95457A0 (en) 1991-06-30
WO1991002541A1 (en) 1991-03-07
CA1339415C (en) 1997-09-02
KR920700686A (ko) 1992-08-10
JPH07121880B2 (ja) 1995-12-25
IL95457A (en) 1997-01-10

Similar Documents

Publication Publication Date Title
RU96101193A (ru) Фрагменты антител в терапии
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
DK79390A (da) Anti-leukocytkonjugat og anvendelse heraf
DE69030545T2 (de) Aufspüren und Behandeln von Infektionen durch Verwendung von Immunokonjukaten
JPS6485928A (en) Monoclonal antibody and peptide useful for therapy and diagnosis for hiv infection
BR9007702A (pt) Metodo de tratamento
KR900013986A (ko) 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도
Fischel et al. The role of tubercle bacilli in adjuvant emulsions on antibody production to egg albumin
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
ATE407149T1 (de) Detoxifizierung durch intramuskulär verabreichte f(ab')2 fragmente
DE60029953D1 (de) Spezifische antikörper gegen humanes choriongonadotropin hormone und deren verwendung in therapie und diagnose
Seed Trypanosoma gambiense and T. equiperdum: Characterization of variant specific antigens
DE69435142D1 (de) Methoden zur Inhibition von HIV-assoziierten Krankheiten mittels monoklonaler Antikörper gegen sich selbstgerichtete zytotoxische T-Zellen
ATE142262T1 (de) Gegen das menschliche immunschwäche-virus gerichtetes immunpräparat
Haines et al. Preparation of specific antisera to cytomegaloviruses in goats
ATE111485T1 (de) Peptidbehandlung von hartnäckigen infektionskrankheiten.
SE9101863D0 (sv) Peptider, diagnostiskt antigen, vaccinkomposition och foerfarande foer selektering av hiv-stammar
Moroz Vipera palaestinae antivenin
RU95117092A (ru) Антитела, смесь антител, fab-фрагмент, линии гибридомных клеток, способы создания линий клеток, способ борьбы с вирусом, способ снижения уровня антигена, днк
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
Dart Antibodies as therapeutic agents: the antivenoms
Repurta ing out such problems of immunity the essential factor
UA28690A (uk) Спосіб діагностики інфекційного ендокардиту стафілококової етіології

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee